Celmatix Therapeutics is focused on advancing women's health through innovative approaches to ovarian function and fertility treatments. The company has developed a deep understanding of ovarian health, recognizing its critical role in overall endocrine function. This understanding has led to the identification of conditions that affect one in three women, which are often inadequately addressed by traditional hormonal treatments that have been in use for over five decades. Celmatix is pioneering new therapeutic strategies, including the development of an oral Follicle Stimulating Hormone receptor (FSHR) agonist, which has the potential to significantly enhance fertility treatments for both men and women.

In addition to its FSHR program, Celmatix is collaborating with Aché Laboratórios to explore novel melatonin receptor agonists aimed at addressing women's health issues, particularly polycystic ovary syndrome (PCOS). This collaboration highlights Celmatix's commitment to filling critical gaps in the market for effective treatments tailored to women's health needs. The company's innovative pipeline reflects a dedication to transforming the landscape of women's health through targeted research and development, ultimately aiming to improve the quality of life for women affected by ovarian health issues.

United States

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information visit www.celmatix.com.

Celmatix

Company Details